SGMT vs. SKYE, CRVO, RPTX, CTMX, PRQR, SYRS, OPTN, RAPT, CYBN, and INCR
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Skye Bioscience (SKYE), CervoMed (CRVO), Repare Therapeutics (RPTX), CytomX Therapeutics (CTMX), ProQR Therapeutics (PRQR), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), RAPT Therapeutics (RAPT), Cybin (CYBN), and InterCure (INCR). These companies are all part of the "pharmaceutical preparations" industry.
Skye Bioscience (NASDAQ:SKYE) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
Sagimet Biosciences has higher revenue and earnings than Skye Bioscience.
Skye Bioscience's return on equity of -61.85% beat Sagimet Biosciences' return on equity.
In the previous week, Sagimet Biosciences had 3 more articles in the media than Skye Bioscience. MarketBeat recorded 10 mentions for Sagimet Biosciences and 7 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.85 beat Sagimet Biosciences' score of 0.55 indicating that Sagimet Biosciences is being referred to more favorably in the news media.
Sagimet Biosciences received 16 more outperform votes than Skye Bioscience when rated by MarketBeat users.
Skye Bioscience presently has a consensus price target of $22.00, suggesting a potential upside of 78.86%. Sagimet Biosciences has a consensus price target of $39.20, suggesting a potential upside of 658.22%. Given Skye Bioscience's higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Skye Bioscience.
21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 0.7% of Skye Bioscience shares are held by company insiders. Comparatively, 17.6% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Sagimet Biosciences beats Skye Bioscience on 11 of the 11 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
